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Abstract 51 
Background Liposomal amphotericin B (LAmB) is widely used in the treatment of invasive 52 
fungal disease (IFD) in adults and children.  There are relatively limited PK data to inform 53 
optimal dosing in children that achieves systemic drug exposures comparable to those of 54 
adults.   55 
Objectives To describe the pharmacokinetics of LAmB in children aged 1-17 years with 56 
suspected or documented IFD. 57 
Methods Thirty-five children were treated with LAmB at dosages of 2.5-10 mg kg-1 daily.  58 
Samples were taken at baseline and at 0.5-2.0 hourly intervals for twenty-four hours after 59 
receipt of the first dose (n=35 patients) and on the final day of therapy (n=25 patients).  60 
LAmB was measured using high performance liquid chromatography (HPLC). The 61 
relationship between drug exposure and development of toxicity was explored. 62 
Results An evolution in PK was observed during the course of therapy resulting in a 63 
proportion of patients (n=13) having significantly higher maximum serum concentration 64 
(Cmax) and area under the concentration time curve (AUC0-24) later in the course of therapy, 65 
without evidence of drug accumulation (Cmin accumulation ratio, AR < 1.2). The fit of a 2-66 
compartment model incorporating weight and an exponential decay function describing 67 
volume of distribution best described the data. There was a statistically significant 68 
relationship between mean AUC0-24 and probability of nephrotoxicity (OR 2.37; 95% CI 69 
1.84-3.22, p=0.004). 70 
Conclusions LAmB exhibits nonlinear pharmacokinetics. A third of children appear to 71 
experience a time-dependent change in PK, which is not explained by weight, maturation or 72 
observed clinical factors.  73 
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Introduction 74 
 The small unilamellar liposomal formulation of amphotericin B (LAmB; 75 
AmBisome®) is widely used for the treatment of invasive fungal disease (IFD) in adults and 76 
children. This compound has been available for over two decades and is a first line agent in 77 
the treatment of serious opportunistic diseases that include invasive aspergillosis, invasive 78 
candidiasis, cryptococcal meningoencephalitis, and mucormycosis. (1-4) 79 
 Despite extensive clinical experience, many of the details relating to the underlying 80 
pharmacological properties of LAmB remain unclear.  A limited number of datasets and 81 
population pharmacokinetic (PK) models have been reported for LAmB. (5-7) These analyses 82 
were based on data gathered from patients receiving relatively low dosages and exclusively 83 
sampled early in the course of therapy. There are very limited data reporting the PK of 84 
LAmB in pediatric populations.  85 
 A better understanding of the pharmacological properties of LAmB remains a priority 86 
and would enable optimal dosing, particularly for special populations such as infants and 87 
children. Dosages ranging from 2.5-10 mg kg-1 per day were studied and each patient was 88 
intensively sampled.  The individual PK profiles for a sub-population of participants (n=25) 89 
were compared at the commencement and end of therapy.  90 
  91 
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Materials & Methods 92 
Patients, Antifungal Regimen 93 
 This study was designed as a prospective, multi-center, open-label phase II clinical 94 
trial. Study protocol approval was obtained from the Ethics Committees of the National 95 
Cancer Institute (Bethesda MD, USA); Children’s National Medical Center (Washington DC, 96 
USA) and Georgetown University Medical Center (Washington DC, USA). Informed consent 97 
was obtained prior to enrolment in each case. A total of 35 children with a diagnosis of 98 
confirmed or suspected IFD were enrolled. Patients received LAmB infused over one hour at 99 
dosages of 2.5, 5.0, 7.5, or 10.0 mg kg-1 daily (n= 9, 13, 8, and 8, respectively). Two patients 100 
received LAmB as treatment for more than one discrete clinical episode requiring antifungal 101 
therapy. Patients undergoing multiple discrete episodes were assigned the same identification 102 
number on each occasion and were handled using the dosing reset function in Pmetrics.    103 
LAmB (AmBisome®; Gilead Sciences, Inc., Foster City, California) was supplied as 104 
a lyophilized powder and stored at 2-8°C until use.  Powder (50 mg) was reconstituted with 105 
12.5 mL of sterile water to a concentration of 4 mg-1 mL, and then further diluted in 5% 106 
dextrose.  Reconstituted drug was used within 6 hours.  107 
Pharmacokinetic Sampling 108 
 PK samples were obtained on the first and last day of therapy. The first day of LAmB 109 
administration was defined as day one. Heparinized whole-blood samples (0.6-1 mL) were 110 
collected by peripheral intravenous catheter. Samples were obtained prior to administration, 111 
and at 0.5-2.0 hourly intervals for 24 hours following the start of each infusion. A total of 7-112 
12 samples were obtained per patient within each sampling period (total sampling blood 113 
volumes < 3 mL/kg within 24 hours). Sampling was repeated in sixteen patients on the last 114 
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day of therapy (12-41 days) using the same sampling schedule.  Plasma fractions were 115 
separated by centrifugation at 1,500 g for 10 min at 4°C and stored at −80°C until analysis. 116 
Concentrations of LAmB in plasma were determined by a high-performance liquid 117 
chromatographic assay. (8) Briefly, total active drug and internal standard, 3-nitrophenol, 118 
were extracted in methanol and separated by reversed-phase chromatography. The separation 119 
was performed isocratically using a Supelcosil ABZ+Plus analytical column (3 µm particle 120 
size, 150 mm x 4.6 mm internal diameter; Supelco, Bellefonte, Pennsylvania), coupled by a 121 
Keysone C18 guard column (3 µm particle size, 7.5 mm x 4.6 mm 7.5 by 4.6 mm; Western 122 
Analytical, Murrieta, California).  The mobile phase, consisting of 10 mM sodium acetate 123 
buffer, including 10 mM EDTA (pH 3.6) and acetonitrile (650:350, vol/vol), was delivered at 124 
a flow rate of 1.0 ml/min using a Spectra-Physics Model 250 pump (Thermo Separations, San 125 
Jose, California). UV absorbency peaks were detected at a wavelength of 406 nm using a 126 
Waters Model 440 UV-VIS detector (Waters Corp, Milford, Massachusetts). Two 127 
overlapping standard curves were used: 0.05 to 20 μg/ml and 0.5 to 200 μg/ml. The assay was 128 
linear over a range of 0.05-20 and 0.5 to 200 µg/mL (r2 >0.995).  Intra- and inter-day 129 
coefficients of variation were 9.5 and 7.0%, and 5.4 and 6.0%, respectively, and the limit of 130 
quantification was 0.05 μg/ml. The average recovery was 90.5% at the concentrations of 131 
quality control samples with a standard deviation of 6.2%. 132 
 133 
Population Pharmacokinetic Modeling 134 
 Data were analysed using a non-parametric methodology within the program Pmetrics 135 
(version 1.2.6; University of Southern California, Los Angeles, CA). (9) The observed data 136 
were weighted using the inverse of the estimated assay variance.  137 
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 Structural models were constructed and used to fit patient data. One-, two- and three-138 
compartment models with zero-order drug input into the central compartment and both first-139 
order and nonlinear (Michaelis-Menten) elimination from the central compartment were 140 
explored. A proportion of patients had concentration-time profiles that indicated an intra-141 
individual change in PK during the course of therapy (n=13; 52%). Affected individuals 142 
demonstrated a marked increase in excursion of drug concentrations from Cmax to Cmin and a 143 
disproportionate increase in AUC0-24  (Figure 1). This change was not associated with rising 144 
trough concentrations, suggesting the phenomenon did not result from drug accumulation 145 
resulting from conventional nonlinear (Michaelis-Menten) kinetics (AR <1.2). Inspection of 146 
the data suggested the clearance of drug was the same in both sampling periods. Hence, the 147 
following structural model that allowed Vd to change with time was explored.  In this model, 148 
volume contracted with time and was described using an exponential decay function. 149 
Clearance (Cl) was scaled according to weight using a standard 0.75 power function. The 150 
differential equations describing the final model were as follows: 151 
 152 
Where: X(1) and X(2) represent the total (bound and free) amount of LAmB (mg) in the 153 
central (c) and peripheral (p) compartments, respectively. R(1), Kcp and Kpc represent the 154 
rate of infusion into the central compartment (mg h-1) and first-order inter-compartmental rate 155 
constants, respectively. Clearance (Cl) is normalised according to a 70 kg individual and 156 
allometrically scaled. The volume of the central compartment (Vc) is described by an 157 
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exponential decay function in which initial volume (Vin) reduced over time according to a 158 
rate constant (K) to a final volume (Vfin). 159 
 The goodness-of-fit of each model to the data was assessed by visual inspection of the 160 
observed-predicted values and following linear regression of the observed-predicted values 161 
both before after the Bayesian step. The coefficient of determination (r2), slope and intercept 162 
of each regression were calculated. Statistical comparison of models was based on likelihood 163 
ratio, in which twice the likelihood difference was evaluated against a χ2 distribution with an 164 
appropriate number of degrees of freedom. In addition, predictive performance was assessed 165 
according to weighted-mean error (a measure of bias) and bias-adjusted weighted-mean-166 
squared error (a measure of precision).  167 
The final selected model was validated using a nonparametric bootstrap resampling 168 
technique. Three hundred bootstrap datasets were constructed based on random sampling 169 
with replacement using ADAPT 5. Measures of central tendency and dispersion and the 95% 170 
confidence interval (CI) for each parameter value were calculated and compared with 171 
estimates from original data. The selected structural model was then implemented within the 172 
simulation module of ADAPT 5. (10) Bayesian estimates of the PK parameters for each 173 
patient were used to calculate simulated peak plasma concentration (Cmax), trough plasma 174 
concentration (Cmin), and area under the concentration time curve over 24 hours (AUC0-24) at 175 
defined therapeutic time points.   176 
 Potential relationships between measures of drug exposure (Cmax, Cmin, absolute 177 
LAmB dosage, weight adjusted dosage, AUC0-24, and mean AUC0-24) and toxicity were 178 
explored. Toxicity was defined as changes from baseline values at commencement of therapy 179 
as follows: nephrotoxicity as an increase in serum creatinine (SCr) of  ≥0.5 mg/dL or 180 
doubling of baseline value, hypokalemia as a fall in potassium of ≤3.0 mmol/L or ≥50% from 181 
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baseline, anemia as an hemoglobin of ≤8.0 g/dL, and hepatotoxicity as a rise in bilirubin by 182 
≥1.5 mg/dL or AST or ALT ≥3 times above baseline. A conservative definition was used to 183 
define change in biological parameters in order to overcome variability in sampling between 184 
patients; pre-treatment value was subtracted from the highest measurement observed for each 185 
patient during the treatment course. 186 
 187 
Results 188 
 The patient demographics of the study cohort are summarized in table 1. The mean ± 189 
SD weight was 26.9 ± 14.0 kg with a range of 8.8-67.5 kg.  There was wide variability in the 190 
duration of therapy: the mean ± SD was 11.9 ± 9.41 days of therapy with a range of 1-41 191 
days.  The most common underlying diagnosis was hematological malignancy (n =21).  Nine 192 
patients had undergone allogeneic hematopoietic stem-cell transplantation (HSCT) and 23 193 
received concomitant antineoplastic chemotherapy. The majority of patients received LAmB 194 
as empirical therapy for suspected IFI (n=31). Seven patients received treatment for 195 
confirmed IFI. There were two cases of invasive aspergillosis due to A. fumigatus, and a 196 
further case that developed during treatment with LAmB that was classified as a 197 
breakthrough infection.  Three patients had invasive candidiasis: one central-line infection 198 
and one severe oesophagitis due to C. albicans, and one case of candidaemia caused by C. 199 
parapsilosis. There was a single case of cryptococcal meningoencephalitis complicating HIV 200 
infection. Clinical success was defined according to clinical, radiological, and mycological 201 
response during the study period plus relapse-free survival at 2 months after the end of 202 
therapy. Clinical success was reported in 76% of probable (n=29) and 43% (n=3) of proven 203 
fungal infections. 204 
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The Bayesian estimates for clearance (Cl) obtained from standard two-compartment models 205 
for each patient were plotted against weight. A relationship between the log10-transformed 206 
estimates was apparent. The performance of models incorporating an allometric power 207 
function was therefore investigated using a scaling exponent fixed at 0.75. No significant 208 
relationship was found between Bayesian estimates for volume (Vd) and weight. Differences 209 
in clinical factors that might be predicted to alter the PK of LAmB were explored. No 210 
significant differences were identified in liver function, serum albumin, white blood cell 211 
(WBC) count and total protein concentrations, use of parenteral nutrition and concomitant 212 
steroids. A relatively poor fit of standard model structures was apparent (see, for example 213 
performance of a standard two-compartment model, figure 2). Conventional compartmental 214 
model structures failed to account for the widening excursion of drug concentrations 215 
observed in a portion of patients. The parameter estimates for the base and final model are 216 
summarized in table 2. The fit of the selected model incorporating a function describing 217 
contraction in Vd was satisfactory (r2 = 0.90), and compared favourably to a standard 2-218 
compartment model. The final model consisted of eight support points. Measures of bias and 219 
precision were acceptable (see figure 2). The bootstrap mean and 95% CI values for 220 
parameters closely approximated the estimates obtained from the final model (table 3), 221 
indicating that the parameter estimates from the final model were robust. Both the mean and 222 
median parameter values resulted in comparable intercept, slopes and overall r2 values.  The 223 
log-likelihood value for the final model was significantly better (more positive) than for the 224 
standard 2-compartment model (χ2 = 48.95, p = <0.001). Figure 3 shows the simulated 225 
concentration-time profiles and raw data for two examples of patients that exhibited time-226 
dependent and time-independent changes in PK profiles.  227 
Dose-exposure relationships were further explored. No correlation between absolute 228 
dose and exposure (Cmax, Cmin or AUC0-24) was observed, an expected finding given the 229 
 
 
12
significant variability in weight within the study population. Significant relationships 230 
between dose per-unit-weight and exposure were observed. Plots of dose-normalized Cmax 231 
and AUC0-24 suggest nonlinearity (figure 4), although a dosing threshold associated with a 232 
discrete change in exposure was not observed. 233 
Transient renal impairment and hypokalemia were common, occurring in 46% (n=16) 234 
and 23% (n=8) of patients, respectively. A significant correlation between steady state 235 
exposure (AUC0-24) and change in serum creatinine (ΔSCr) was observed (Figure 5, r=0.594, 236 
p=0.015). A statistically significant relationship between mean AUC0-24 and probability of 237 
developing nephrotoxicity (OR 2.37; 95% CI 1.84-3.22, p=0.004). There was insufficient 238 
clinical information to explore the impact of other potential determinants of renal impairment 239 
(for example disease severity and concomitant nephrotoxic drugs) in this study cohort.  No 240 
significant correlations were found between LAmB exposure (in terms of absolute dose, 241 
weight adjusted dose, AUC0-24 or mean AUC0-24) and other toxicity including hypokalemia, 242 
anemia, and hepatotoxicity. 243 
 244 
Discussion 245 
 Liposomal amphotericin B is used extensively for the treatment of IFD.  Dosages of 246 
3-6 mg kg-1 are approved in the U.S.A and the E.U. in both adults and children.  These 247 
dosages are not based on an in-depth knowledge of the pharmacology of the drug, but rather 248 
results from preclinical in vivo studies and clinical trials that have attempted to identify 249 
regimens that appear safe and effective. There continues to be considerable uncertainty 250 
regarding the lowest effective dosage of LAmB that achieves adequate antifungal effect.  As 251 
a result, dosages of 1-15 mg kg-1 have been studied in a range of clinical settings including 252 
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empirical therapy, invasive aspergillosis, invasive candidiasis, and cryptococcal 253 
meningoencephalitis. (11-14)  254 
 Phase I/II clinical studies of LAmB in children and adults have highlighted variable, 255 
dose-dependent PK. Children and adults receiving LAmB at conservative daily doses of 1-3 256 
mg kg-1 exhibit linear PK that are described by standard two- or three-compartment models 257 
with first-order elimination. (6, 7)(5) Limited data suggest nonlinearity at higher dosages. 258 
Walsh et al. observed time-dependent nonlinear PK and an apparent paradoxical dose-259 
dependent exposure plateau in adults receiving daily dosages of 7.5-15 mg kg-1. (3) The data 260 
from paediatric patients in this study similarly suggests that a proportion of patients exhibit 261 
time-dependent nonlinear PK. When the concentration-time profiles of patients exhibiting 262 
nonlinear PK are examined a significant excursion in Cmin-Cmin is observed, a change not 263 
associated with a proportional increase in half-life that would be expected with classical 264 
nonlinear (Michaelis-Menten) clearance, but rather appears to reflect a contraction in the 265 
volume of distribution during the course of therapy. Whereas the limited data from adults has 266 
suggested a paradoxical dose-dependent reduction in exposure at doses >7.5 mg kg-1, in 267 
children higher doses appear to be associated with an increased probability of nonlinearity. 268 
The reason for this difference is unclear and warrants further study.   269 
High-density lipoproteins (HDL) mediated opsonization of lipid formulations of 270 
amphotericin B within plasma has been shown to drive uptake into mononuclear phagocytes 271 
and deposition within the liver and spleen. (15-18) Hong et al. reported a negative correlation 272 
between Bayesian estimates volume of distribution and the fraction of HDL-associated 273 
LAmB in 21 children and adolescence receiving LAmB at daily doses of 0.8-6 mg kg-1. We 274 
hypothesize that variable HDL saturation and/or phagocyte uptake may be the 275 
pathophysiological processes driving the inter-individual variability observed in this study. 276 
However, many patients in this small clinical cohort exhibited significant fluctuations in 277 
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hematological parameters such as WBC count over the course of antifungal therapy, 278 
primarily due to underlying hemato-oncological diagnoses, and we were not able to further 279 
characterise relationships between specific hematological parameters and volume contraction. 280 
Other significant data such as plasma HDL concentrations were not quantified in this study. 281 
This is an interesting hypothesis that warrants further study in experimental models and/or as 282 
part of larger clinical trials. LAmB is generally well tolerated with a significantly improved 283 
toxicity profile when compared to conventional amphotericin B deoxycholate. (14) Dosages 284 
of LAmB as high as 15 mg kg-1 daily have been reportedly well tolerated in adults. (3) A 285 
number of studies including one large RCT have, however, described dose-dependent toxicity 286 
with significantly higher rates of renal impairment and hypokalemia at dosages at or above 10 287 
mg kg-1 daily. (1) In this study, a significant proportion of patients developed transient renal 288 
impairment and/or hypokalemia during the course of treatment. In view of the limited data 289 
available, significant inter-individual variability and lack of obvious inflection point in this 290 
relationship further analysis to define exposure thresholds was not possible. The correlation 291 
between drug exposure and ΔSCr observed here suggests, however, that clinical vigilance 292 
and assiduous monitoring of renal function is required to minimize the probability of toxicity 293 
associated with LAmB. 294 
 Taken together these data suggest that a significant proportion of pediatric patients 295 
receiving LAmB at daily doses > 5.0 mg kg-1 exhibit nonlinear PK with significantly higher 296 
peak concentrations and overall drug exposure. This phenomenon was not predicted by 297 
clinical covariates quantified in this study. Therapeutic drug monitoring (TDM) is thus likely 298 
to be of value in identifying this subpopulation in order to prevent toxicity. Effective 299 
implementation of TDM would require a more detailed understand of exposure-toxicity 300 
relationships and data describing disease severity in children with proven or probably IFD in 301 
order to define target exposure thresholds. 302 
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Table 1 Patient demographics of cohorts undergoing sampling on day one of therapy and at 397 
steady state  398 
 399 
Demographic Day one (n=35)  Steady state  (n=25)  
Age (μ ± SD, range; years) 8.7 ± 4.6 (1 - 17)  10.5 ± 6.6 (1 - 17) 
Gender (M:F) 22:13 15:10 
Weight (μ ± SD, range; kg) 26.9 ± 14.0 (8.8 - 67.5) 25.4 ± 16.2 (11.2 – 67.5) 
Duration of therapy (μ ± SD, 
range; days) 
11.9 ± 19.4 (1 - 41) 15.5 ± 11.3 (9.5 - 41) 
Underlying diagnosis (no. 
patients) 
  
     Hematopoietic stem cell 
transplant 
  
              Leukemia 6 5 
              Sickle cell disease 1 1 
              Aplastic anemia  1 0 
     Chemotherapy   
               Leukemia 8 5 
               Lymphoma 7 5 
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               Solid tumor 7 4 
     HIV 4 4 
     Chronic granulomatous 
disease 
1 1 
Clinical syndrome (no. patients)   
     Established infection  6 6 
     Empiric treatment  29 19 
Pathogen    
     Candida albicans 2 2 
     Candida parapsilosis 1 1 
     Aspergillus fumigatus 3 3 
     Cryptosporidium 1 1 
Clinical response   
     Success 29 21 
     Failure  8 4 
     Breakthrough 1 0 
 400 
 401 
1402 
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 Table 2. The parameter estimates for the final 2-compartment pharmacokinetic model 403 
 404 
CV%, coefficient of variation; Vin, initial volume of distribution; Vfin, final volume of 405 
distribution; K, first-order inter-volume rate constant; Kcp/Kpc, first-order inter-406 
compartmental rate constants; Cl, clearance.  407 
 408 
 409 
 410 
 411 
 412 
 413 
Parameter Vin (L) Vfin (L) Kcp(h-1) Kpc(h-1) K (h-1) Cl (L  h-1 70 kg-1) 
Base model 
Mean 4.543 n/a 0.28 0.888 n/a 0.488 
Median 4.095 n/a 0.184 0.254 n/a 0.545 
Standard Deviation 3.44 n/a 0.252 0.387 n/a 0.29 
Error (CV%) 75.72 n/a 90.025 43.581 n/a 59.426 
Selected model 
Mean 10.654 2.326 0.21 0.057 0.303 0.67 
Median 7.998 2.986 0.178 0.033 0.027 0.665 
Standard Deviation 1.523 0.978 0.130 0.01 0.094 0.239 
Error (CV%) 14.295 42.064 61.905 17.544 31.023 35.672 
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Table 3. Bootstrap estimates of the selected pharmacokinetic model 415 
 416 
 417 
 418 
Figure 1. Concentration-time profiles for each patient on day one of therapy (n=35) and at 419 
completion of therapy (n=25). Closed circles are the raw pharmacokinetic data from each 420 
patient.  421 
 422 
Figure 2. Scatter plots showing observed-versus-predicted values for population 423 
pharmacokinetic models after the Bayesian step with a standard 2-compartment model (A) 424 
and selected model (B). Open circles, dashed lines and solid lines represent individual 425 
Parameter Bootstrap Final model 
 Mean estimate 95% CI Mean estimate 95% CI 
Vin (L) 10.677 10.646 – 10.87 10.654 10.67 – 10.87 
Vfin (L) 2.345 2.181 – 3.023 2.326 2.162 – 3.01 
Kcp (h-1) 0.311 0.127 – 0.42 0.210 0.108 – 0.388 
Kpc (h-1) 0.057 0.043 – 0.061 0.057 0.043 – 0.061 
K (h-1) 0.303 0.21 – 0.355 0.302 0.21 – 0.351 
Cl (L  h-1 70 kg-1) 0.675 0.555 – 0.781 0.670 0.548 – 0.797 
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observed-predicted data points, line of identity, and the linear regression of observed-426 
predicted values, respectively. 427 
 428 
Figure 3. Concentration-time profiles for two patients receiving LAmB (10 mg kg-1). Initial 429 
(Vin) and final (Vfin) estimates for volume of distribution (Vd) are shown. Open circles and 430 
solid lines represent the raw data and simulated concentration-time profiles for each patient, 431 
respectively. Patient A exhibits evolving PK with a contraction in the Vd while patient B 432 
exhibits stable Vd.  433 
 434 
Figure 4 Comparisons of dose-normalised Cmax (A) and AUC0-24 (B) at steady state with 435 
respect to dose per unit weight. Solid and dashed lines represent linear regression and 95% 436 
confidence intervals, respectively. 437 
 438 
Figure 5. Relationship between Bayesian estimates of AUC0-24 at steady state with respect to 439 
change in serum creatinine. Solid and dashed lines represent linear regression and 95% 440 
confidence intervals, respectively.  441 
 442 





